About this file

This document is an Inclusion Enrollment Report for a human subjects research study. It contains information about the planned and actual enrollment of participants, including their racial and ethnic categories, gender, and other demographic details. The study is focused on certain conditions or research areas, and has eligibility criteria regarding participants' age range. The document includes sections on protection and monitoring plans, study design and outcomes, and other clinical trial-related attachments. However, it does not provide details about any specific product or service being procured through a federal contract opportunity.

The related federal contract opportunity is a solicitation for Small Business Innovation Research (SBIR) or Small Business Technology Transfer (STTR) Phase I and/or Direct to Phase II or Fast Track contracts in support of the Advanced Research Projects Agency for Health (ARPA-H)'s FY2024 program areas. The solicitation covers topics such as ambulatory edema monitors, predictive language models for cognitive disability adaptive communication tools, cell and gene therapy process analytical technology, wearable cell sorting and gene delivery systems, precision brain targeting, personalized food as medicine, inner ear imaging devices, and advanced blood pressure monitoring technologies. Proposals are due by July 15, 2024, and the contracting agency is the General Services Administration's Federal Acquisition Service.

View the file

Other files

File Type Posted
47QFCA24R0036_Amend 0004_ARPA-H FY24 SBIR SOLITICATION (1).pdf PDF
SF30_Amendment 0004_47QFCA24R0036_.pdf PDF
APPENDIX C - Phase II Technical Proposal_Amendment 0004.docx DOCX document
APPENDIX B - Phase I Business Proposal_Amendment 0004.docx DOCX document
APPENDIX F - Self Certification Checklist.pdf PDF
APPENDIX D - Phase II Business Proposal_Amendment 0004.docx DOCX document
APPENDIX A - Phase I Technical Proposal_Amendment 0004.docx DOCX document
47QFCA24R0036 Amendment 03 QA.pdf PDF
47QFCA24R0036_Amend 0003_ARPA-H FY24 SBIR SOLITICATION.pdf PDF
SF 30_Amendment 0003_47QFCA24R0036.pdf PDF
47QFCA24R0036_Amend 0002_Solic ARPA-H.pdf PDF
APPENDIX B - Phase I Business Proposal_Amendment 0002.pdf PDF
APPENDIX D - Phase II Business Proposal_Amendment 0002.pdf PDF
47QFCA24R0036 Amendment 02_QA.pdf PDF
SF30 - Amendment 0002_47QFCA24R00036.pdf PDF
Standard Form 30 - Amendment 0001 Solicitation_Modification of Contract.pdf PDF
47QFCA24R0036_Amend 0001_Solic_ARPA-H .pdf PDF
47QFCA24R0036 Amendment 0001 QA.pdf PDF
APPENDIX D - Phase II Business Proposal (2).docx DOCX document
APPENDIX A - Phase I Technical Proposal (2).docx DOCX document
APPENDIX E General Clauses.docx DOCX document
APPENDIX C - Phase II Technical Proposal (2).docx DOCX document
ARPA-H FY24 SBIR SOLITICATION 47QFCA24R0036.pdf PDF
APPENDIX A.1 — HUMAN SUBJECTS AND CLINICAL TRIALS INFORMATION FORM (4).pdf PDF
APPENDIX B - Phase I Business Proposal (2).docx DOCX document
Show all 25

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

* Always required field

Study Record: PHS Human Subjects and Clinical Trials Information

OMB Number: 0925-0001

Expiration Date: 01/31/2026

Section 1 - Basic Information

1.1. * Study Title (each study title must be unique)

1.2. * Is this Study Exempt from Federal Regulations?

1.3. Exemption Number

1 2 3 4 5 6 7 8

1.4. * Clinical Trial Questionnaire

If the answers to all four questions below are yes, this study meets the definition of a Clinical Trial.

1.4.a. Does the study involve human participants? Yes No

1.4.b. Are the participants prospectively assigned to an intervention? Yes No

1.4.c. Is the study designed to evaluate the effect of the intervention on the participants? Yes No

1.4.d. Is the effect that will be evaluated a health-related biomedical or behavioral outcome? Yes No

1.5. Provide the ClinicalTrials.gov Identifier (e.g., NCT87654321) for this trial, if applicable

Section 2 - Study Population Characteristics

2.1. Conditions or Focus of Study

2.2. Eligibility Criteria

2.3. Age Limits Minimum Age Maximum Age

2.3.a. Inclusion of Individuals Across the Lifespan

2.4. Inclusion of Women and Minorities

2.5. Recruitment and Retention Plan

2.6. Recruitment Status

2.7. Study Timeline

2.8. Enrollment of First Participant

2.9. Inclusion Enrollment Report(s)

Yes No

View Attachment Add Attachment Delete Attachment

View Attachment Add Attachment Delete Attachment

View Attachment Add Attachment Delete Attachment

View Attachment Add Attachment Delete Attachment x

Add New Condition

Add Inclusion Enrollment Report

Inclusion Enrollment Report

OMB Number: 0925-0770

Expiration Date: 09/30/2024

1. * Inclusion Enrollment Report Title

2. * Using an Existing Dataset or Resource

3. * Enrollment Location Type

4. Enrollment Country(ies)

5. Enrollment Location(s)

6. Comments

Remove Inclusion Enrollment Report

Yes No

Domestic Foreign x

Add New Country

Planned

Racial Categories

Ethnic Categories

Not Hispanic or Latino Hispanic or Latino Total

Female Male Female Male

American Indian/

Alaska Native

Asian

Native Hawaiian or

Other Pacific Islander

Black or African

American

White

More than One Race

Total

Cumulative (Actual)

Racial Categories

Ethnic Categories

Not Hispanic or Latino Hispanic or Latino Unknown/Not Reported Ethnicity Total

Female

Male

Unknown/

Not

Reported

American Indian/

Alaska Native

Asian

Native Hawaiian or

Other Pacific Islander

Black or African

American

White

More than One Race

Unknown or Not

Total

Report 1 of 1

< Previous Report Next Report >

|<< First Report Delete Report Last Report >>|

Section 3 - Protection and Monitoring Plans

3.1. Protection of Human Subjects

3.2. Is this a multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site?

Yes No N/A

4.1. Study Design

4.1.a. Detailed Description

4.1.b. Primary Purpose

4.1.c. Interventions x Intervention Type

Name

Description

4.1.d. Study Phase

Is this an NIH-defined Phase III clinical trial? Yes No

4.1.e. Intervention Model

4.1.f. Masking

Yes

Participant

No

Care Provider Investigator Outcomes Assessor

4.1.g. Allocation

Single IRB plan attachment Add Attachment Delete Attachment View Attachment

3.3. Data and Safety Monitoring Plan Add Attachment Delete Attachment View Attachment

3.4. Will a Data and Safety Monitoring Board be appointed for this study?

Yes No

3.5. Overall Structure of the Study Team Add Attachment Delete Attachment View Attachment

Section 4 - Protocol Synopsis

Add New Intervention

4.2. Outcome Measures

x Name

Type

Time Frame

Brief Description

4.3. Statistical Design and Power

4.4. Subject Participation Duration

4.5. Will the study use an FDA-regulated intervention? Yes No

4.5.a. If yes, describe the availability of Investigational Product (IP) and Investigational New Drug (IND)/Investigational

Device Exemption (IDE) status

4.6. Is this an applicable clinical trial under FDAAA? Yes No

4.7. Dissemination Plan

Section 5 - Other Clinical Trial-related Attachments

5.1. Other Clinical Trial-related Attachments

View Attachment Add Attachment Delete Attachment

View Attachments Add Attachments Delete Attachments

Add New Outcome

File details come from the government source that posted it. Updated .